Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Pasadena, California, focused on developing innovative medicines for intractable diseases. The company's core business revolves around silencing disease-causing genes through the mechanism of RNA interference (RNAi). Its mission is to develop medicines that treat these challenging conditions by targeting the genetic origins of disease.

Central to Arrowhead's approach is its proprietary Targeted RNAi Molecule (TRiM™) platform, which enables the design of targeted RNAi therapeutics. The company's pipeline addresses a range of therapeutic areas, including cardiometabolic, pulmonary, liver, and neuromuscular diseases. Key products include REDEMPLO® (plozasiran), an siRNA medicine approved in the United States, Australia, and Europe as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). Other clinical candidates, such as Zodasiran (ARO-ANG3), ARO-INHBE, and ARO-PNPLA3, are in various stages of development targeting conditions like severe hypertriglyceridemia, obesity, and metabolic dysfunction-associated steatohepatitis (MASH).

Led by President, CEO, and Chairman of the Board, Dr. Christopher Anzalone, Arrowhead Pharmaceuticals is transitioning from a research-focused entity to a commercial-stage company. Recent notable developments include receiving European Commission marketing authorization for REDEMPLO® (plozasiran) in June 2026. The company also reported strong commercial launch momentum for REDEMPLO® and positive clinical data for its RNAi-based obesity and MASH candidate, ARO-INHBE, at EASL 2026. In May 2026, Arrowhead licensed its ARO-PNPLA3 program to Madrigal Pharmaceuticals. The company's strategic focus includes a hybrid monetization strategy, combining high-value licensing deals with direct product sales for its core assets.